Results 21 to 30 of about 788,607 (367)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors

Clinical Pharmacology: Advances and Applications, 2015
Pontus B Persson Institute of Vegetative Physiology, Berlin, GermanyApixaban and rivaroxaban are oral factor Xa inhibitors. In a recent issue of Clinical Pharmacology: Advances and Applications, Frost et al compare apixaban (2.5 mg, twice daily) to ...
Persson PB
doaj   +5 more sources

Factor Xa Inhibitors Versus Vitamin K Antagonists in Atrial Fibrillation Patients with End-Stage Kidney Disease on Dialysis: A Meta-Analysis [PDF]

Clinical and Applied Thrombosis/Hemostasis
Background Atrial fibrillation (AF) is prevalent among patients with end-stage kidney disease (ESKD) undergoing dialysis, and both conditions are associated with a heightened risk of cardiovascular diseases.
Meimei Xiong MS, Linjuan Guo MD, Yun Wan MS   +2 more
doaj   +2 more sources

Andexanet alfa for the reversal of factor Xa inhibitors

Expert Opinion on Biological Therapy, 2019
Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. Since May 2018, the FDA has approved its utilization in patients treated with apixaban and rivaroxaban in case of life-threatening or uncontrolled bleeding.
J Favresse, M Hardy, MA van Dievoet, AL Sennesael, J Douxfils, CM Samama, O Vornicu, AS Dincq, S Lessire, F Mullier   +9 more
openaire   +5 more sources

Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors [PDF]

TH Open
Background Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.
Mark Goldin, Kolton Smith, Ioannis Koulas, Tungming Leung, Mayuri Ravi, Sanjit Parhar, Sejal Shah, Kayla Floyd, Lori Ohanesian, Rachel Bain, Daniella Defonte, Kanta Ochani, Amanda Lin, Bhumi Patel, Nikolaos Tsaftaridis, Jack Jnani, Alex C. Spyropoulos   +16 more
doaj   +2 more sources

Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey [PDF]

Clinical and Applied Thrombosis/Hemostasis
Direct oral factor Xa inhibitors are replacing vitamin K-dependent antagonists as anticoagulation treatment in many clinical scenarios. Trauma centers are noting an increase in patients presenting on these medications.
Charles Fasanya MD, FRCS FACS, Abenámar Arrillaga MD FACS FCCP, Catherine Caronia MD, MBA, Lauren Rothburd BS, Tenzing Japhe BA, Younghee Hahn BS, Paul Joseph BS, Dajana Reci BA, Patricia Eckardt PhD, RN, FAAN   +8 more
doaj   +3 more sources

Fondaparinux sodium: A selective inhibitor of factor Xa

American Journal of Health-System Pharmacy, 2001
The pharmacology and mechanism of action of fondaparinux sodium are described. Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. It has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response.
Kenneth A. Bauer
openaire   +4 more sources

Factor Xa Inhibitor

Japanese Journal of Thrombosis and Hemostasis, 2003
Takashi KOIZUMI, Masahiko UCHIDA
openaire   +4 more sources

Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland

Swiss Medical Weekly, 2023
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but ...
Anne Angelillo-Scherrer, Alessandro Casini, Jan-Dirk Studt, Bernhard Gerber, Lorenzo A. Alberio, Pierre Fontana   +5 more
doaj   +1 more source

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Circulation, 2023
Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b ...
T. Milling, S. Middeldorp, Lizhen Xu, Bruce R Koch, A. Demchuk, J. Eikelboom, P. Verhamme, A. Cohen, J. Beyer-Westendorf, C. Michael Gibson, J. López-Sendón, M. Crowther, A. Shoamanesh, M. Coppens, Jeannot Schmidt, P. Albaladéjo, S. Connolly, R. Anand, A. Bastani, C. Clark, M. Concha, J. Cornell, K. Dombrowski, G. Fermann, J. Fulmer, J. Goldstein, D. Kereiakes, T. Milling, D. Pallin, N. Patel, M. Refaai, M. Rehman, A. Schmaier, E. Schwarz, W. Shillinglaw, M. Spohn, T. Takata, A. Venkat, J. Welker, I. Welsby, J. Wilson, L. Van Keer, F. Verschuren, M. Blostein, J. Eikelboom, K. Althaus, J. Berrouschot, G. Braun, T. Doeppner, R. Dziewas, S. Genth‐Zotz, P. Greinacher, F. Hamann, F. Hanses, W. Heide, B. Kallmuenzer, P. Kermer, S. Poli, G. Royl, S. Schellong, S. Schnupp, J. Schwarze, C. Spies, G. Thomalla, M. von Mering, K. Weissenborn, F. Wollenweber, C. Gumbinger, U. Jaschinski, M. Maschke, H. Mochmann, W. Pfeilschifter, C. Pohlmann, R. Zahn, P. Bouzat, J. Schmidt, C. Vallejo, B. Floccard, M. Coppens, S. V. van Wissen, E. Arellano-Rodrigo, E. Vallès, R. Alikhan, K. Breen, R. Hall, M. Crowther, P. Albaladéjo, A. Cohen, A. Demchuk, D. Wyse, D. A. Garcia, M. Prins, J. Nakamya, H. Büller, K. Mahaffey, J. Alexander, J. Cairns, R. Hart, C. Joyner, G. Raskob, S. Schulman, R. Veltkamp, B. Meeks, E. Zotova, Sahar Ahmad, T. Pinto, K. Baker, A. Dykstra, I. Holadyk-Gris, Antonio Malvaso   +109 more
semanticscholar   +1 more source

Prediction of inhibition constants of (R)-3-amidinophenylalanine inhibitors toward factor Xa by 2D-QSAR model

Vietnam Journal of Science, Technology and Engineering, 2022
A coagulation cascade forms through proteolytic reactions and involves different factors. There are two coagulation pathways, including intrinsic and extrinsic mechanisms, which converge by the formation of factor Xa.
Thi Bich Van Pham, Minh Hao Hoang
doaj   +1 more source